Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults
NCT ID: NCT04265105
Last Updated: 2023-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
18 participants
INTERVENTIONAL
2021-12-22
2023-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
NCT03363191
Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response
NCT01128569
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
NCT01706198
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma
NCT02301975
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
NCT01453023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
standard of care
Short acting beta agonist or inhaled corticosteroids
Standard Preparation
inhaled SABA or Inhaled corticosteroid
fluticasone-vilanterol
LABA-ICS A combination of Long acting beta agonist and inhaled corticosteroid
fluticasone-vilanterol
LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fluticasone-vilanterol
LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid
Standard Preparation
inhaled SABA or Inhaled corticosteroid
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal College of Surgeons in Ireland - Medical University of Bahrain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Ghufran Jassim
Associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RCSI Bahrain
Al Muharraq, Busaiteen, Bahrain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RCSIBahrain
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.